抗 SARS-CoV-2 单克隆抗体在美国食品药品监督管理局撤销授权后的使用。
Administration of Anti-SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization.
机构信息
Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
出版信息
JAMA Netw Open. 2022 Aug 1;5(8):e2228997. doi: 10.1001/jamanetworkopen.2022.28997.
Abstract
This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.
摘要
这项横断面研究使用时间序列数据评估了美国食品和药物管理局在 2022 年初取消了巴姆洛单抗-埃特司韦单抗和卡司瑞韦单抗-伊德韦单抗单克隆抗体治疗 SARS-CoV-2 感染的使用授权后的使用情况。
Zotero 插件